

B1

1. (Amended) A method of beneficially regulating gastrointestinal motility in a subject comprising administering to said subject a therapeutically effective amount of an exendin or an exendin agonist, wherein said exendin agonist is an exendin analog or derivative, and thereby beneficially regulating said gastrointestinal motility in said subject.

B2

9. (Amended) A method according to claim 1, 2 or 3 wherein said [gastric] gastrointestinal motility is associated with a gastrointestinal disorder.

Please cancel non-elected claims 12-19 without prejudice. Although Applicants previously traversed the Examiner's restriction requirement, that requirement has now been made final. Applicants reserve the right to pursue the subject matter of these claims in this or any other appropriate patent application. The cancellation of these claims is not intended to constitute, does not constitute, and may not be construed to constitute an admission against interest regarding the patentability of this subject matter.

In claim 20, after "Xaa₁₈-Z" please insert -- (SEQ. ID. NO. 38) --

In claim 21, after "Xaa₁₈-Z" please insert -- (SEQ. ID. NO. 39) --

Please add new claims 22-30 as follows:

4B-
22. The method of claim 1, wherein said exendin analog or derivative has an activity about 1% to about 10,000% of the activity of the exendin of which it is an analog or derivative.

23. The method of claim 1, wherein said exendin analog or derivative has an activity about 10% to about 1,000% of the activity of the exendin of which it is an analog or derivative.

24. The method of claim 1, wherein said exendin derivative has an activity about 50% to about 500% of the activity of the exendin of which it is an analog or derivative.

25. The method of claim 1, wherein said exendin derivative has at least about 50% sequence similarity to the exendin of which it is an analog or derivative.

26. The method of claim 1, wherein said exendin derivative has at least about 70% sequence similarity to the exendin of which it is an analog or derivative.

27. The method of claim 1, wherein said exendin derivative has at least about 90% sequence similarity to the exendin of which it is an analog or derivative.